This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Somboonporn, W. Articles by Davis, S. R. Search for Related Content PubMed PubMed Citation Articles by Somboonporn, W. Articles by Davis, S. R.

Testosterone Effects on the Breast: Implications for Testosterone Therapy for Women

The National Health and Medical Research Council Centre of Clinical Research Excellence for the Study of Women’s Health at the Jean Hailes Foundation and the Department of Obstetrics and Gynaecology, Monash University, Clayton, Victoria 3168, Australia

Correspondence: Address all correspondence and requests for reprints to: Professor Susan R. Davis, The Jean Hailes Foundation NHMRC Centre of Clinical Research Excellence, 173 Carinish Road, Clayton, Victoria 3168, Australia. E-mail: susan.davis{at}jeanhailes.org.au

Androgens have important physiological effects in women. Postmenopausal androgen replacement, most commonly as testosterone therapy, is becoming increasingly widespread. This is despite the lack of clear guidelines regarding the diagnosis of androgen insufficiency, optimal therapeutic doses, and long-term safety data. With respect to the breast specifically, there is the potential for exogenous testosterone to exert either androgenic or indirect estrogenic actions, with the latter potentially increasing breast cancer risk. In experimental studies, androgens exhibit growth-inhibitory and apoptotic effects in some, but not all, breast cancer cell lines. Differing effects between cell lines appear to be due primarily to variations in concentrations of specific coregulatory proteins at the receptor level. In rodent breast cancer models, androgen action is antiproliferative and proapoptotic, and is mediated via the androgen receptor, despite the potential for testosterone and dehydroepiandrosterone to be aromatized to estrogen. The results from studies in rhesus monkeys suggest that testosterone may serve as a natural endogenous protector of the breast and limit mitogenic and cancer-promoting effects of estrogen on mammary epithelium. Epidemiological studies have significant methodological limitations and provide inconclusive results. The strongest data for exogenous testosterone therapy comes from primate studies. Based on such simulations, inclusion of testosterone in postmenopausal estrogen-progestin regimens has the potential to ameliorate the stimulating effects of combined estrogen-progestin on the breast. Research addressing this is warranted; however, the number of women that would be required for an adequately powered randomized controlled trial renders such a study unlikely.

This article has been cited by other articles:

				S. R. Davis, M. Moreau, R. Kroll, C. Bouchard, N. Panay, M. Gass, G. D. Braunstein, A. L. Hirschberg, C. Rodenberg, S. Pack, et al. Testosterone for Low Libido in Postmenopausal Women Not Taking Estrogen N. Engl. J. Med., November 6, 2008; 359(19): 2005 - 2017. [Abstract] [Full Text] [PDF]

				C. L Shufelt and G. D Braunstein Testosterone and the breast Menopause Int, September 1, 2008; 14(3): 117 - 122. [Abstract] [Full Text] [PDF]

				A. Mueller and L. Gooren Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones Eur. J. Endocrinol., September 1, 2008; 159(3): 197 - 202. [Abstract] [Full Text] [PDF]

				E. A. Ariazi, A. Leitao, T. I. Oprea, B. Chen, T. Louis, A. M. Bertucci, C. G.N. Sharma, S. D. Gill, H. R. Kim, H. A. Shupp, et al. Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen Mol. Cancer Ther., November 1, 2007; 6(11): 2817 - 2827. [Abstract] [Full Text] [PDF]

				S. Wedren, C. Magnusson, K. Humphreys, H. Melhus, A. Kindmark, F. Stiger, M. Branting, I. Persson, J. Baron, and E. Weiderpass Associations between Androgen and Vitamin D Receptor Microsatellites and Postmenopausal Breast Cancer Cancer Epidemiol. Biomarkers Prev., September 1, 2007; 16(9): 1775 - 1783. [Abstract] [Full Text] [PDF]

				S. N. Birrell, L. M. Butler, J. M. Harris, G. Buchanan, and W. D. Tilley Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer FASEB J, August 1, 2007; 21(10): 2285 - 2293. [Abstract] [Full Text] [PDF]

				M. Hietala, T. Sandberg, A. Borg, H. Olsson, and H. Jernstrom Testosterone levels in relation to oral contraceptive use and the androgen receptor CAG and GGC length polymorphisms in healthy young women Hum. Reprod., January 1, 2007; 22(1): 83 - 91. [Abstract] [Full Text] [PDF]

				S. Basaria and A. S. Dobs Controversies Regarding Transdermal Androgen Therapy in Postmenopausal Women J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 4743 - 4752. [Abstract] [Full Text] [PDF]

				M. E. Wierman, R. Basson, S. R. Davis, S. Khosla, K. K. Miller, W. Rosner, and N. Santoro Androgen Therapy in Women: An Endocrine Society Clinical Practice Guideline J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3697 - 3710. [Abstract] [Full Text] [PDF]

				G. Perez-Palacios, R. Santillan, R. Garcia-Becerra, E. Borja-Cacho, F. Larrea, P. Damian-Matsumura, L. Gonzalez, and A. E Lemus Enhanced formation of non-phenolic androgen metabolites with intrinsic oestrogen-like gene transactivation potency in human breast cancer cells: a distinctive metabolic pattern. J. Endocrinol., September 1, 2006; 190(3): 805 - 818. [Abstract] [Full Text] [PDF]

				M. H. Slagter, L. J.G. Gooren, A. Scorilas, C. D. Petraki, and E. P. Diamandis Effects of Long-term Androgen Administration on Breast Tissue of Female-to-Male Transsexuals J. Histochem. Cytochem., August 1, 2006; 54(8): 905 - 910. [Abstract] [Full Text] [PDF]

				R. M. Tamimi, S. E. Hankinson, W. Y. Chen, B. Rosner, and G. A. Colditz Combined Estrogen and Testosterone Use and Risk of Breast Cancer in Postmenopausal Women Arch Intern Med, July 24, 2006; 166(14): 1483 - 1489. [Abstract] [Full Text] [PDF]

				B. Gabriel, D.-C Fischer, M. Orlowska-Volk, A. zur Hausen, R. Schule, J. M. Muller, and A. Hasenburg Expression of the Transcriptional Coregulator FHL2 in Human Breast Cancer: A Clinicopathologic Study Reproductive Sciences, January 1, 2006; 13(1): 69 - 75. [Abstract] [PDF]

				T. Suzuki, Y. Miki, Y. Nakamura, T. Moriya, K. Ito, N. Ohuchi, and H. Sasano Sex steroid-producing enzymes in human breast cancer Endocr. Relat. Cancer, December 1, 2005; 12(4): 701 - 720. [Abstract] [Full Text] [PDF]

				W. Wang, E. M. John, and S. A. Ingles Androgen Receptor and Prostate-Specific Antigen Gene Polymorphisms and Breast Cancer in African-American Women Cancer Epidemiol. Biomarkers Prev., December 1, 2005; 14(12): 2990 - 2994. [Abstract] [Full Text] [PDF]

				G. Buchanan, S. N. Birrell, A. A. Peters, T. Bianco-Miotto, K. Ramsay, E. J. Cops, M. Yang, J. M. Harris, H. A. Simila, N. L. Moore, et al. Decreased Androgen Receptor Levels and Receptor Function in Breast Cancer Contribute to the Failure of Response to Medroxyprogesterone Acetate Cancer Res., September 15, 2005; 65(18): 8487 - 8496. [Abstract] [Full Text] [PDF]

				S R Davis, I Dinatale, L Rivera-Woll, and S Davison Postmenopausal hormone therapy: from monkey glands to transdermal patches J. Endocrinol., May 1, 2005; 185(2): 207 - 222. [Abstract] [Full Text] [PDF]

				L.M. Rivera-Woll, M. Papalia, S.R. Davis, and H.G. Burger Androgen insufficiency in women: diagnostic and therapeutic implications Hum. Reprod. Update, September 1, 2004; 10(5): 421 - 432. [Abstract] [Full Text] [PDF]